Handelsbanken Fonder Ab Sage Therapeutics, Inc. Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$18.62 - $26.95 $22,344 - $32,340	1,200 Added 9.49%	13,844 $259,000
Q4 2023 Feb 01, 2024	BUY	$17.1 - $22.26 $49,590 - $64,554	2,900 Added 29.76%	12,644 $274,000
Q2 2021 Aug 03, 2021	SELL	$54.88 - $79.29 $10,976 - $15,858	-200 Reduced 2.01%	9,744 $554,000
Q4 2020 Feb 11, 2021	BUY	$58.41 - $89.06 $105,138 - $160,308	1,800 Added 22.1%	9,944 $860,000
Q2 2020 Aug 13, 2020	BUY	$25.95 - $43.15 $211,336 - $351,413	8,144 New	8,144 $339,000

218

48.2M

854K

195K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $395M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.